FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1946708754> ?p ?o ?g. }

• W1946708754 endingPage "iv267" @default.
• W1946708754 startingPage "iv267" @default.
• W1946708754 abstract "ABSTRACT Aim: Hsp90 is a molecular chaperone required for the proper folding and function of multiple client proteins including the androgen receptor (AR). AT13387 (AT), a synthetic Hsp90 inhibitor displays activity against multiple prostate cancer models. A 2-part, Phase 1/2, randomized study was initiated to investigate the combination of AT + AA/P in mCRPC pts progressing on AA. Methods: The primary objectives were the safety and tolerability of AT/AA/P and to select the treatment regimen for the Ph2, based on assessment of safety and antitumor activity. Secondary endpoints included pharmacokinetics (PK), pharmacodynamics (PD), and progression-free survival (PFS). Part 1 used a rolling six design to determine the maximum tolerated dose (MTD) of the AT/AA/P combination. All pts continued to receive oral AA/P (1000 mg Qd/5 mg BID) at progression, being randomized to receive 1 of 2 AT dosing regimens: AT at the starting dose of 220 mg/m2 IV once weekly for 3 weeks (R1), or 120 mg/m2 on Days 1 & 2 weekly for 3 weeks (R2) in a 4-week cycle. PD studies evaluated AR expression in tissue and circulating tumor cells (CTC) pre and post AT treatment. Results: Overall 48 patients were treated (R1: AT at 220-260 mg/m2; R2: AT at 120-160 mg/m2). The most frequent AT- treatment related ≥ Grade 3 toxicities were diarrhea (21%) and fatigue (13%). Diarrhea was dose-limiting for both regimens (AT at 260 mg/m2 and 160 mg/m2 for R1 and R2, respectively). PK analysis showed that AT exposures were similar to what was observed in previous studies while AA exposures appeared to be ∼30% lower when co-administered with AT. PD analyses indicated limited target knockdown. Multiple subjects showed transient decreases in PSA but no PCWG2 PSA responses or objective RECIST tumor responses were observed and the study did not proceed to Ph2. Conclusions: Our study represents the first clinical trial of an Hsp90 inhibitor in combination with AA/P. MTDs were reached for once-weekly (220 mg/m2) and twice-weekly (120 mg/m2) regimens; however AT + AA/P did not demonstrate adequate antitumor activity at these doses for the study to proceed to Part 2. Disclosure: J. Garcia: grants/research Support & consultant/independent contractor for JJ N.J. Vogelzang: Research funding from Astex; A. Oganesian, L. Manlapaz-Espiritu, Y. Hao and H. Keer: Astex employee. All other authors have declared no conflicts of interest." @default.
• W1946708754 created "2016-06-24" @default.
• W1946708754 creator A5000011430 @default.
• W1946708754 creator A5001745177 @default.
• W1946708754 creator A5002891676 @default.
• W1946708754 creator A5006496749 @default.
• W1946708754 creator A5011166011 @default.
• W1946708754 creator A5014912122 @default.
• W1946708754 creator A5018384442 @default.
• W1946708754 creator A5034354367 @default.
• W1946708754 creator A5035164790 @default.
• W1946708754 creator A5036494803 @default.
• W1946708754 creator A5036678244 @default.
• W1946708754 creator A5048986055 @default.
• W1946708754 creator A5051729520 @default.
• W1946708754 creator A5052252975 @default.
• W1946708754 creator A5053749991 @default.
• W1946708754 creator A5056587248 @default.
• W1946708754 creator A5059219836 @default.
• W1946708754 creator A5070875530 @default.
• W1946708754 creator A5072378199 @default.
• W1946708754 creator A5079843750 @default.
• W1946708754 date "2014-09-01" @default.
• W1946708754 modified "2023-10-05" @default.
• W1946708754 title "A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to Aa" @default.
• W1946708754 doi "https://doi.org/10.1093/annonc/mdu336.24" @default.
• W1946708754 hasPublicationYear "2014" @default.
• W1946708754 type Work @default.
• W1946708754 sameAs 1946708754 @default.
• W1946708754 citedByCount "2" @default.
• W1946708754 countsByYear W19467087542015 @default.
• W1946708754 countsByYear W19467087542016 @default.
• W1946708754 crossrefType "journal-article" @default.
• W1946708754 hasAuthorship W1946708754A5000011430 @default.
• W1946708754 hasAuthorship W1946708754A5001745177 @default.
• W1946708754 hasAuthorship W1946708754A5002891676 @default.
• W1946708754 hasAuthorship W1946708754A5006496749 @default.
• W1946708754 hasAuthorship W1946708754A5011166011 @default.
• W1946708754 hasAuthorship W1946708754A5014912122 @default.
• W1946708754 hasAuthorship W1946708754A5018384442 @default.
• W1946708754 hasAuthorship W1946708754A5034354367 @default.
• W1946708754 hasAuthorship W1946708754A5035164790 @default.
• W1946708754 hasAuthorship W1946708754A5036494803 @default.
• W1946708754 hasAuthorship W1946708754A5036678244 @default.
• W1946708754 hasAuthorship W1946708754A5048986055 @default.
• W1946708754 hasAuthorship W1946708754A5051729520 @default.
• W1946708754 hasAuthorship W1946708754A5052252975 @default.
• W1946708754 hasAuthorship W1946708754A5053749991 @default.
• W1946708754 hasAuthorship W1946708754A5056587248 @default.
• W1946708754 hasAuthorship W1946708754A5059219836 @default.
• W1946708754 hasAuthorship W1946708754A5070875530 @default.
• W1946708754 hasAuthorship W1946708754A5072378199 @default.
• W1946708754 hasAuthorship W1946708754A5079843750 @default.
• W1946708754 hasBestOaLocation W19467087541 @default.
• W1946708754 hasConcept C104317684 @default.
• W1946708754 hasConcept C121608353 @default.
• W1946708754 hasConcept C126322002 @default.
• W1946708754 hasConcept C126894567 @default.
• W1946708754 hasConcept C143998085 @default.
• W1946708754 hasConcept C185592680 @default.
• W1946708754 hasConcept C205260736 @default.
• W1946708754 hasConcept C2775832370 @default.
• W1946708754 hasConcept C2777899217 @default.
• W1946708754 hasConcept C2778720950 @default.
• W1946708754 hasConcept C2779256933 @default.
• W1946708754 hasConcept C2780192828 @default.
• W1946708754 hasConcept C55493867 @default.
• W1946708754 hasConcept C71315377 @default.
• W1946708754 hasConcept C71924100 @default.
• W1946708754 hasConcept C98274493 @default.
• W1946708754 hasConceptScore W1946708754C104317684 @default.
• W1946708754 hasConceptScore W1946708754C121608353 @default.
• W1946708754 hasConceptScore W1946708754C126322002 @default.
• W1946708754 hasConceptScore W1946708754C126894567 @default.
• W1946708754 hasConceptScore W1946708754C143998085 @default.
• W1946708754 hasConceptScore W1946708754C185592680 @default.
• W1946708754 hasConceptScore W1946708754C205260736 @default.
• W1946708754 hasConceptScore W1946708754C2775832370 @default.
• W1946708754 hasConceptScore W1946708754C2777899217 @default.
• W1946708754 hasConceptScore W1946708754C2778720950 @default.
• W1946708754 hasConceptScore W1946708754C2779256933 @default.
• W1946708754 hasConceptScore W1946708754C2780192828 @default.
• W1946708754 hasConceptScore W1946708754C55493867 @default.
• W1946708754 hasConceptScore W1946708754C71315377 @default.
• W1946708754 hasConceptScore W1946708754C71924100 @default.
• W1946708754 hasConceptScore W1946708754C98274493 @default.
• W1946708754 hasLocation W19467087541 @default.
• W1946708754 hasOpenAccess W1946708754 @default.
• W1946708754 hasPrimaryLocation W19467087541 @default.
• W1946708754 hasRelatedWork W2034119386 @default.
• W1946708754 hasRelatedWork W2399301633 @default.
• W1946708754 hasRelatedWork W2620798309 @default.
• W1946708754 hasRelatedWork W2886632102 @default.
• W1946708754 hasRelatedWork W2913908103 @default.
• W1946708754 hasRelatedWork W2943917324 @default.
• W1946708754 hasRelatedWork W3011636404 @default.
• W1946708754 hasRelatedWork W4361884858 @default.
• W1946708754 hasRelatedWork W4361884954 @default.

• next